Namibia vs Senegal: Average cost of multi drug-resistant tuberculosis treatment
Namibia
3,336 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Namibia rank
14th
Senegal rank
12th
Average cost of multi drug-resistant tuberculosis treatment over time
- Namibia
- Senegal
How they compare
Senegal currently reports 3,428 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia, a difference of 92 constant 2022 US$.
The two have swapped places 2 times across 5 shared years of data; in 2019 it was Senegal ahead.
Namibia ranks 14th and Senegal ranks 12th of 92 countries.
Across the 2 decades both report, Namibia averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Namibia | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,580 constant 2022 US$ | 4,290 constant 2022 US$ | 710 constant 2022 US$ | Senegal |
| 2020s | 3,028 constant 2022 US$ | 2,913 constant 2022 US$ | 115.5 constant 2022 US$ | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Namibia or Senegal?
- Senegal, at 3,428 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Namibia and Senegal?
- 92 constant 2022 US$, with Senegal ahead.
- How many years of comparable data are there for Namibia and Senegal?
- 5 years are reported by both, from 2019 to 2024.
- How do Namibia and Senegal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Namibia ranks 14th and Senegal ranks 12th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.